摘要
目的:分析培门冬酶注射液致2例患者凝血障碍的原因,为合理用药提供参考。方法:对病例-1患者因中枢神经系统淋巴瘤/白血病第6次入院;病例-2患者因急性混合细胞白血病(双表型T/髓)入院,均给予行VIDLP方案化疗,分析其致患者凝血障碍的原因。结果:病例-1培门冬酶致患者凝血障碍,第14天出现鼻衄,予以输注血浆纠正凝血异常,治疗后逐渐恢复;病例-2致患者凝血障碍,给予输注新鲜冰冻血浆100 m L纠正凝血紊乱,给药后第17天予以输注纤维蛋白原纠正出凝血紊乱;经救治2例患者凝血功能逐渐恢复。结论:培门冬酶注射液在临床使用中应予高度重视,谨慎使用,发现上述反应应予及时救治。
Objective： To analyze the reason of coagulopathy induced by pegaspargase injection in 2 patients, and to provide reference for the rational use of this drug. Methods： Case-1 was sixth times hospitalized with central nervous system lymphoma/Leukemia; case-2 was hospitalized with mixed cell acute leukemia. Both of them were treated with VIDLP treatment programs, and the cause of coagulopathy was analyzed. Results： Case-1 developed coagulopathy： on 14th day after injection with pegasparga, the patient had epistaxis and plasma was infusioned to rectify it. Case-2 devel- oped coagulopathy： 100 mL plasma infusion was given, and on 17th day, fibrinogen was injected to rectify coagulopathy. Alter treatment, the coagulation of the 2 patients was gradually recovered. Conclusion： Pegaspargase injection should be paid great attentian and had to be carefull in clinical use. importance and caution in clinical use. Once discovered the patient should be timely given treatment.
出处
《抗感染药学》
2015年第2期245-247,共3页
Anti-infection Pharmacy
关键词
培门冬酶
凝血障碍
药品不良反应
pegasparga injection
coagulopathy
adverse drug reaction
